Generic Name and Formulations:
Progesterone (micronized) 100mg, 200mg; caps; contains peanut oil.
Virtus Pharmaceuticals, Inc.
Indications for PROMETRIUM:
To prevent endometrial hyperplasia in postmenopausal women with an intact uterus receiving conjugated estrogens. Secondary amenorrhea.
Endometrial hyperplasia prevention: 200mg once daily in the PM for 12 sequential days of each 28-day cycle. Amenorrhea: 400mg once daily in the PM for 10 days.
Undiagnosed vaginal bleeding. Breast or genital carcinoma. Severe liver dysfunction or disease. Missed abortion. Thrombophlebitis, thromboembolic disorders, cerebral apoplexy. Not for use as a diagnostic test for pregnancy. Peanut allergy. Pregnancy (Cat.B).
Conditions that may be aggravated by fluid retention. Renal or hepatic dysfunction. Depression. Discontinue if thrombotic disorders, papilledema, or retinal vascular lesions occur. Do initial and annual physical exam (include BP, PAP smear, mammogram). Discontinue pending exam if visual disturbances or migraine occurs. Monitor diabetics. Nursing mothers: not recommended.
Dizziness, mastodynia, headache, abdominal pain/bloating, fatigue, musculoskeletal pain, emotional lability, GI upset, vaginal discharge.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|